SE9501782D0 - Method of predicting the therapeutic response of a drug against a malignant tumour - Google Patents

Method of predicting the therapeutic response of a drug against a malignant tumour

Info

Publication number
SE9501782D0
SE9501782D0 SE9501782A SE9501782A SE9501782D0 SE 9501782 D0 SE9501782 D0 SE 9501782D0 SE 9501782 A SE9501782 A SE 9501782A SE 9501782 A SE9501782 A SE 9501782A SE 9501782 D0 SE9501782 D0 SE 9501782D0
Authority
SE
Sweden
Prior art keywords
tumour
cells
therapeutic response
sample
pct
Prior art date
Application number
SE9501782A
Other languages
English (en)
Swedish (sv)
Inventor
Leif Haakansson
Annika Haakansson
Bertil Gustafsson
Original Assignee
Landstinget I Oestergoetland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landstinget I Oestergoetland filed Critical Landstinget I Oestergoetland
Priority to SE9501782A priority Critical patent/SE9501782D0/xx
Publication of SE9501782D0 publication Critical patent/SE9501782D0/xx
Priority to CA002215627A priority patent/CA2215627A1/en
Priority to US08/952,140 priority patent/US6114128A/en
Priority to EP96919762A priority patent/EP0824696B1/en
Priority to PT96919762T priority patent/PT824696E/pt
Priority to ES96919762T priority patent/ES2151665T3/es
Priority to DE69610496T priority patent/DE69610496T2/de
Priority to DK96919762T priority patent/DK0824696T3/da
Priority to PCT/EP1996/002007 priority patent/WO1996035949A1/en
Priority to AT96919762T priority patent/ATE196688T1/de
Priority to JP8533784A priority patent/JPH11504715A/ja
Priority to GR20000402580T priority patent/GR3034891T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9501782A 1995-05-12 1995-05-12 Method of predicting the therapeutic response of a drug against a malignant tumour SE9501782D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9501782A SE9501782D0 (sv) 1995-05-12 1995-05-12 Method of predicting the therapeutic response of a drug against a malignant tumour
JP8533784A JPH11504715A (ja) 1995-05-12 1996-05-10 悪性腫瘍に対する薬の治療応答を予測するための方法及びキット
PT96919762T PT824696E (pt) 1995-05-12 1996-05-10 Processo e kit para a previsao da resposta terapeutica duma droga usada contra um tumor maligno
US08/952,140 US6114128A (en) 1995-05-12 1996-05-10 Method and kit for predicting the therapeutic response of a drug against a malignant tumor
EP96919762A EP0824696B1 (en) 1995-05-12 1996-05-10 Method and kit for predicting the therapeutic response of a drug against a malignant tumour
CA002215627A CA2215627A1 (en) 1995-05-12 1996-05-10 Method and kit for predicting the therapeutic response of a drug against a malignant tumour
ES96919762T ES2151665T3 (es) 1995-05-12 1996-05-10 Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno.
DE69610496T DE69610496T2 (de) 1995-05-12 1996-05-10 Verfahren zur vorhersage der therapeutischen antwort eines medikamentes auf einen malignen tumoren
DK96919762T DK0824696T3 (da) 1995-05-12 1996-05-10 Fremgangsmåde og kit til at forudsige den terapeutiske reaktion på et medikament mod en malign tumor
PCT/EP1996/002007 WO1996035949A1 (en) 1995-05-12 1996-05-10 Method and kit for predicting the therapeutic response of a drug against a malignant tumour
AT96919762T ATE196688T1 (de) 1995-05-12 1996-05-10 Verfahren zur vorhersage der therapeutischen antwort eines medikamentes auf einen malignen tumoren
GR20000402580T GR3034891T3 (en) 1995-05-12 2000-11-22 Method and kit for predicting the therapeutic response of a drug against a malignant tumour

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501782A SE9501782D0 (sv) 1995-05-12 1995-05-12 Method of predicting the therapeutic response of a drug against a malignant tumour

Publications (1)

Publication Number Publication Date
SE9501782D0 true SE9501782D0 (sv) 1995-05-12

Family

ID=20398299

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501782A SE9501782D0 (sv) 1995-05-12 1995-05-12 Method of predicting the therapeutic response of a drug against a malignant tumour

Country Status (12)

Country Link
US (1) US6114128A (el)
EP (1) EP0824696B1 (el)
JP (1) JPH11504715A (el)
AT (1) ATE196688T1 (el)
CA (1) CA2215627A1 (el)
DE (1) DE69610496T2 (el)
DK (1) DK0824696T3 (el)
ES (1) ES2151665T3 (el)
GR (1) GR3034891T3 (el)
PT (1) PT824696E (el)
SE (1) SE9501782D0 (el)
WO (1) WO1996035949A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
US5824467A (en) * 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
US20030096237A1 (en) * 2000-08-28 2003-05-22 Ulrich Certa Determination of the ability of patients to respond to a tumor treatment
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
SG10201406457VA (en) 2009-10-19 2014-11-27 Rostaquo S P A Methods and systems for pharmacogenomic treatment of cardiovascular conditions
WO2012024236A1 (en) * 2010-08-14 2012-02-23 Biogen Idec Ma Inc. LTβR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system

Also Published As

Publication number Publication date
DE69610496T2 (de) 2001-05-10
CA2215627A1 (en) 1996-11-14
EP0824696A1 (en) 1998-02-25
ATE196688T1 (de) 2000-10-15
DE69610496D1 (de) 2000-11-02
PT824696E (pt) 2001-03-30
US6114128A (en) 2000-09-05
DK0824696T3 (da) 2001-01-02
EP0824696B1 (en) 2000-09-27
GR3034891T3 (en) 2001-02-28
WO1996035949A1 (en) 1996-11-14
JPH11504715A (ja) 1999-04-27
ES2151665T3 (es) 2001-01-01

Similar Documents

Publication Publication Date Title
Shin et al. Monocytoid B-cell lymphoma in patients with Sjögren's syndrome: a clinicopathologic study of 13 patients
BR9917218A (pt) Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas
EP0852004A2 (en) MULTIPLEXED ANALYSIS OF CLINICAL SPECIMENS
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
CA1305928C (en) Monoclonal antibody specific to a novel epitope of the lfa-1 antigen of human t lymphocytes
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
SE9500023D0 (sv) Method of detecting cancer
Bloom et al. In vitro methods in cell-mediated immunity: a progress report
EP0352722A3 (en) Adenocarcinoma antigen binding methods and reagents
PL309637A1 (en) Diagnostic test and therapy for demyelination diseases such as multiple sclerosis
SE9501782D0 (sv) Method of predicting the therapeutic response of a drug against a malignant tumour
AU6828387A (en) Assay for human breast cancer
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
Armitage et al. Normal and certain leukaemic B cells express IL-2 receptors without in vitro activation.
Emmitt et al. Crossed immunoelectrophoresis: qualitative and quantitative considerations
DE3688638T2 (de) Monoklonale Antikörper für humane Lungenkarzinome des "Nicht-kleine-Zellen"-Typs.
PL322209A1 (en) Detection of antibody production
CA2286335A1 (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
SE9501780D0 (sv) Monitoring immunotherapy of malignant tumours
Bean et al. Factors That Affect the Results of Microcytotoxicity Testing in Man 1, 2, 3
GODFREY et al. SOME RECENT THESES ON THE THYMUS AND RELATED TOPICS
Taylor et al. Immunohistologic techniques: their impact in tumor diagnosis with particular reference to lymphomas